217 related articles for article (PubMed ID: 33343721)
1. First-line immune-checkpoint inhibitor plus chemotherapy
Landre T; Chouahnia K; Des Guetz G; Duchemann B; Assié JB; Chouaïd C
Ther Adv Med Oncol; 2020; 12():1758835920977137. PubMed ID: 33343721
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
3. Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses.
Gristina V; Galvano A; Castellana L; Insalaco L; Cusenza S; Graceffa G; Iacono F; Barraco N; Castiglia M; Perez A; Rizzo S; Russo A; Bazan V
Ther Adv Med Oncol; 2021; 13():17588359211018018. PubMed ID: 34646363
[TBL] [Abstract][Full Text] [Related]
4. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.
Arriola E; González-Cao M; Domine M; De Castro J; Cobo M; Bernabé R; Navarro A; Sullivan I; Trigo JM; Mosquera J; Crama L; Isla D
Oncol Ther; 2022 Jun; 10(1):167-184. PubMed ID: 35032007
[TBL] [Abstract][Full Text] [Related]
5. Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials.
Facchinetti F; Di Maio M; Tiseo M
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32947924
[TBL] [Abstract][Full Text] [Related]
6. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
[TBL] [Abstract][Full Text] [Related]
7. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
8. Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis.
Sathiyapalan A; Febbraro M; Pond GR; Ellis PM
Curr Oncol; 2022 Nov; 29(12):9046-9065. PubMed ID: 36547123
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.
Yang C; Xuan T; Gong Q; Dai X; Wang C; Zhang R; Zhao W; Wang J; Yue W; Li J
Thorac Cancer; 2024 May; 15(15):1246-1262. PubMed ID: 38623838
[TBL] [Abstract][Full Text] [Related]
10. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
[TBL] [Abstract][Full Text] [Related]
11. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis.
Villacampa G; Tolosa P; Salvador F; Sánchez-Bayona R; Villanueva L; Dienstmann R; Ciruelos E; Pascual T
Cancer Treat Rev; 2022 Mar; 104():102352. PubMed ID: 35144055
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Wang BC; Xiao BY; Li PC; Kuang BH; Chen WB; Li PD; Lin GH; Liu Q
J Oncol; 2020; 2020():2368164. PubMed ID: 33061969
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer.
Lu J; Lei X; Zhang P; Du L; Zhang Z; Qu B
Cancer Med; 2023 Sep; 12(17):17924-17933. PubMed ID: 37563966
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis.
Li H; Han H; Li C; Wu R; Wang Z; Wang Y; Zhan P; Lv T; Zhang F; Song Y; Liu H
Ther Adv Med Oncol; 2023; 15():17588359231189430. PubMed ID: 37885460
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety comparison of PD-1 inhibitors
Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of addition immune checkpoint inhibitors to chemotherapy as first-line treatment for small cell lung cancer patients with liver or brain metastases: a systematic review and meta-analysis.
Chen CR; Qi WX; Liu T; Tong X
Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5857-5867. PubMed ID: 36066161
[TBL] [Abstract][Full Text] [Related]
18. Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer.
Xie Z; Liu J; Wu M; Wang X; Lu Y; Han C; Cong L; Li J; Meng X
J Clin Med; 2023 Jun; 12(11):. PubMed ID: 37298023
[TBL] [Abstract][Full Text] [Related]
19. Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis.
Lin Y; Jiang W; Su CY; Pan XB
Aging (Albany NY); 2023 Sep; 15(18):9561-9571. PubMed ID: 37724893
[TBL] [Abstract][Full Text] [Related]
20. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
Front Oncol; 2022; 12():978069. PubMed ID: 36330494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
